<?php /*Template Name: Why Rebyota*/
get_header();
the_post();
?>
<main class="page__home">
    <section class="hero hero--alt"
        style="background-image: url('<?php echo get_template_directory_uri(); ?>/uploads/hero2.jpg')">
        <div class="container">
            <h1 class="hero__title hero__title--alt ">Why <strong><span>RE</span>BYOTA<sup>Â®</sup></strong>
            </h1>
        </div>
        <div class="hero__banner">
            <div class="hero__bannerInner hero__bannerInner--fullWidth">
                <div class="container">
                    <p>REBYOTA is the first and only FDA-approved microbiota-based live biotherapeutic to reduce
                        recurrence of C. difficile infection
                        <strong>STARTING AT FIRST RECURRENCE.<sup>1</sup></strong>
                    </p>
                </div>
            </div>
        </div>
    </section>

    <div class="backgroundWrapper backgroundWrapper--alt"
        style="background-image: url('<?php echo get_template_directory_uri(); ?>/uploads/backgroundWrapper.jpg')">

        <section class="sectionTitle">
            <div class="container">
                <div class="sectionTitle__wrap">
                    <h2 class="sectionTitle__title">STUDIED IN <strong>MORE THAN 1000 PATIENTS</strong><br />
                        ACROSS 6 CLINICAL TRIALS
                    </h2>
                    <p><strong>More than 700 out of 1000 patients were treated with
                            REBYOTA.</strong><br />
                        Evaluation was consistent across microbial composition, endpoints, and
                        populations.<sup>1,2</sup>
                    </p>
                </div>
            </div>
        </section>

        <section class="fancyCard">
            <div class="container">
                <div class="fancyCard__wrap">
                    <div class="fancyCard__wrapInner">
                        <table class="fancyCard__table">
                            <tr>
                                <th class="fancyCard__head fancyCard__head--larger">
                                    <p>Study design criteria<sub class="sub">1,3</sub></p>
                                </th>
                                <th class="fancyCard__head">
                                    <p><strong>PUNCH<sub class="super super--smaller">TM</sub></strong> CD (Phase 2)
                                    </p>
                                </th>
                                <th class="fancyCard__head">
                                    <p><strong>PUNCH<sub class="super super--smaller">TM</sub></strong> CD2 (Phase 2b)
                                    </p>
                                </th>
                                <th class="fancyCard__head">
                                    <p><strong>PUNCH<sub class="super super--smaller">TM</sub></strong> Open-Label
                                        (Phase 2)
                                    </p>
                                </th>
                                <th class="fancyCard__head">
                                    <p><strong>PUNCH<sub class="super super--smaller">TM</sub></strong> CD3 (Phase 3)
                                    </p>
                                </th>
                                <th class="fancyCard__head">
                                    <p><strong>PUNCH<sub class="super super--smaller">TM</sub></strong> CD3-OLS (Phase
                                        3)
                                    </p>
                                </th>
                                <th class="fancyCard__head">
                                    <p><strong>Real-World Retrospective Study</strong>
                                </th>
                            </tr>
                            <tr>
                                <td class="fancyCard__content fancyCard__content--larger">
                                    <p>Total Patients Enrolled</p>
                                </td>
                                <td class="fancyCard__content ">
                                    <p>N=40</p>
                                </td>
                                <td class="fancyCard__content ">
                                    <p>N=150</p>
                                </td>
                                <td class="fancyCard__content ">
                                    <p>N=272</p>
                                </td>
                                <td class="fancyCard__content ">
                                    <p>N=320</p>
                                </td>
                                <td class="fancyCard__content ">
                                    <p>N=483 <br><em>Interim data; enrollment ongoing</em></p>
                                </td>
                                <td class="fancyCard__content ">
                                    <p>N=94</p>
                                </td>
                            </tr>
                            <tr>
                                <td class="fancyCard__content fancyCard__content--larger">
                                    <p><strong>CONSISTENT</strong> Population:
                                        patients with recurrent CDI</p>
                                </td>
                                <td class="fancyCard__content "><svg class="icon icon-tick">
                                        <use xlink:href="#icon-tick"></use>
                                    </svg>
                                </td>
                                <td class="fancyCard__content "><svg class="icon icon-tick">
                                        <use xlink:href="#icon-tick"></use>
                                    </svg>
                                </td>
                                <td class="fancyCard__content "><svg class="icon icon-tick">
                                        <use xlink:href="#icon-tick"></use>
                                    </svg>
                                </td>
                                <td class="fancyCard__content "><svg class="icon icon-tick">
                                        <use xlink:href="#icon-tick"></use>
                                    </svg>
                                </td>
                                <td class="fancyCard__content "><svg class="icon icon-tick">
                                        <use xlink:href="#icon-tick"></use>
                                    </svg>
                                </td>
                                <td class="fancyCard__content "><svg class="icon icon-tick">
                                        <use xlink:href="#icon-tick"></use>
                                    </svg>
                                </td>
                            </tr>
                            <tr>
                                <td class="fancyCard__content fancyCard__content--larger">
                                    <p><strong>CONSISTENT</strong> Composition
                                        <span class="font-regular">Broad consotium of bacteria</span>
                                    </p>
                                </td>
                                <td class="fancyCard__content "><svg class="icon icon-tick">
                                        <use xlink:href="#icon-tick"></use>
                                    </svg>
                                </td>
                                <td class="fancyCard__content "><svg class="icon icon-tick">
                                        <use xlink:href="#icon-tick"></use>
                                    </svg>
                                </td>
                                <td class="fancyCard__content "><svg class="icon icon-tick">
                                        <use xlink:href="#icon-tick"></use>
                                    </svg>
                                </td>
                                <td class="fancyCard__content "><svg class="icon icon-tick">
                                        <use xlink:href="#icon-tick"></use>
                                    </svg>
                                </td>
                                <td class="fancyCard__content "><svg class="icon icon-tick">
                                        <use xlink:href="#icon-tick"></use>
                                    </svg>
                                </td>
                                <td class="fancyCard__content "><svg class="icon icon-tick">
                                        <use xlink:href="#icon-tick"></use>
                                    </svg>
                                </td>
                            </tr>
                            <tr>
                                <td class="fancyCard__content fancyCard__content--larger">
                                    <p><strong>CONSISTENT</strong> Endpoint
                                        <span class="font-regular">Absence of CDI diarrhea within 8 weeks</span>
                                    </p>
                                </td>
                                <td class="fancyCard__content "><svg class="icon icon-tick">
                                        <use xlink:href="#icon-tick"></use>
                                    </svg>
                                </td>
                                <td class="fancyCard__content "><svg class="icon icon-tick">
                                        <use xlink:href="#icon-tick"></use>
                                    </svg>
                                </td>
                                <td class="fancyCard__content "><svg class="icon icon-tick">
                                        <use xlink:href="#icon-tick"></use>
                                    </svg>
                                </td>
                                <td class="fancyCard__content "><svg class="icon icon-tick">
                                        <use xlink:href="#icon-tick"></use>
                                    </svg>
                                </td>
                                <td class="fancyCard__content "><svg class="icon icon-tick">
                                        <use xlink:href="#icon-tick"></use>
                                    </svg>
                                </td>
                                <td class="fancyCard__content ">
                                    <p>Safety</p>
                                </td>
                            </tr>
                            <tr>
                                <td class="fancyCard__content fancyCard__content--larger">
                                    <p><strong>Study Type</strong></p>
                                </td>
                                <td class="fancyCard__content ">
                                    <p>Open-label</p>
                                </td>
                                <td class="fancyCard__content ">
                                    <p>Randomized, controlled</p>
                                </td>
                                <td class="fancyCard__content ">
                                    <p>Open-label</p>
                                </td>
                                <td class="fancyCard__content ">
                                    <p>Randomized, controlled</p>
                                </td>
                                <td class="fancyCard__content ">
                                    <p>Open-label</p>
                                </td>
                                <td class="fancyCard__content ">
                                    <p>Open-label</p>
                                </td>
                            </tr>
                            <tr>
                                <td class="fancyCard__content fancyCard__content--larger fancyCard__content--border">
                                    <p><strong>Follow-Up Duration</strong></p>
                                </td>
                                <td class="fancyCard__content fancyCard__content--border">
                                    <p>6 months</p>
                                </td>
                                <td class="fancyCard__content fancyCard__content--border">
                                    <p>24 months</p>
                                </td>
                                <td class="fancyCard__content fancyCard__content--border">
                                    <p>24 months</p>
                                </td>
                                <td class="fancyCard__content fancyCard__content--border">
                                    <p>6 months</p>
                                </td>
                                <td class="fancyCard__content fancyCard__content--border">
                                    <p>6 months</p>
                                </td>
                                <td class="fancyCard__content fancyCard__content--border">
                                    <p>6 months</p>
                                </td>
                            </tr>
                        </table>
                    </div>
                </div>
            </div>
        </section>

        <section class="fancyCard">
            <div class="container">
                <h2 class="sectionTitle__title"><strong>Pivotal Phase 3 Trial</strong>
                </h2>
                <ul class="fancyCard__list">
                    <li>Evaluated 320 patients with documented recurrent CDI (1 recurrence after a primary episode of
                        CDIa or â¥2 episodes of severe CDI recurrences resulting in hospitalization within the last
                        year<sup>1,3</sup></li>
                    <li><strong>32.3% of patients treated were at first CDI recurrence<sup>1,3</sup></strong></li>
                </ul>
                <div class="fancyCard__wrap">
                    <div class="fancyCard__wrapInner">
                        <div class="fancyCard__text">
                            <p><strong>Investigator's choice: </strong>Diagnostic test(s) used and selection of
                                antibiotic to
                                address active infection.<sup>b</sup></p>
                            <p><strong>No bowel prep:</strong> Patients did not receive prep prior to REBYOTA treatment.
                            </p>
                        </div>
                        <figure class="fancyCard__image">
                            <img src="<?php echo get_template_directory_uri() ?> /uploads/flowchart.png"
                                alt="Flowchart" />
                        </figure>
                    </div>
                </div>
                <div class="fancyCard__textBottom">
                    <p><sup>a</sup>Patients also must have completed â¥1 round of SoC antibiotic therapy.<sup>1,3</sup>
                    </p>
                    <p><sup>b</sup>CDI diagnosis confirmed 30 days before study enrollment via PCR, EIA, GDH, toxin
                        A or B presence, or other CDI diagnostic test. Antibiotics (vancomycin, vancomycin in
                        combination, fidaxomicin, or other) administered â¥10 consecutive days before
                        washout.<sup>1,3</sup>
                    </p>
                </div>
            </div>
        </section>

        <section class="fancyCard">
            <div class="container">
                <h2 class="sectionTitle__title"><span class="logo logo--large"><strong>RE</strong>BYOTA</span><strong>
                        REDUCED CDI RECURRENCEâ</strong>AT 8 WEEKS
                </h2>
                <div class="fancyCard__wrap fancyCard__wrap--alt">
                    <div class="fancyCard__wrapInner">
                        <div class="fancyCard__description">
                            <p><strong>Primary Endpoint:</strong> REBYOTA demonstrated a statistically significant
                                <strong>70.4% (126/177) treatment success rate<sup>c</sup> at 8 weeks. <br>Placebo was
                                    58.1% (53/85).<sup>1,3</sup></strong>
                            </p>
                            <p>Of those patients who saw success, <strong>91.2% (115/126) had a 70.4% (116/126)
                                    sustained response through 6 months.<br>Placebo was 90.6%.
                                    (48/53)<sup>1,3</sup></strong> </p>
                        </div>
                        <div class="fancyCard__fancyText">
                            <p>No statistically significant difference in
                                treatment response<sup>1,3</sup> based onâ¦</p>
                            <p><strong>Number of prior CDI episode<sup>sd</sup> â¢ Age<sup>d</sup> â¢ Sex â¢ Race</strong>
                            </p>
                        </div>
                        <figure class="fancyCard__imageAbsoulte">
                            <img src="<?php echo get_template_directory_uri() ?> /uploads/flower2.png"
                                alt="Flowchart" />
                        </figure>

                    </div>
                </div>
                <div class="fancyCard__textBottom">
                    <p><sup>c</sup>Treatment success was defined as no CDI-related diarrhea at 8
                        weeks.<sup>1,3</sup>
                    </p>
                    <p><sup>d</sup>dSubgroup of CDI episodes was â¤3 vs >3 episodes; subgroup of age was <65 vs â¥65
                            years.<sup>1,3</sup></p>
                </div>
            </div>
        </section>

        <section class="fancyCard">
            <div class="container">
                <div class="fancyCard__top">
                    <h2 class="fancyCard__title">REBYOTA safety profile
                    </h2>
                    <p><strong>Adverse reactions with an incidence of â¥5% reported in REBYOTA- and placebo-treated
                            adults in the
                            blinded portion of the phase 3 trial (safety population)1,3e</strong></p>
                </div>
                <div class="fancyCard__wrap">
                    <div class="fancyCard__wrapInner">
                        <table class="fancyCard__table">
                            <tr>
                                <th class="fancyCard__head fancyCard__head--alt fancyCard__head--larger">
                                    <p>ADVERSE EVENT</p>
                                </th>
                                <th class="fancyCard__head fancyCard__head--alt">
                                    <p><strong>REBYOTA</strong> n=180
                                    </p>
                                </th>
                                <th class="fancyCard__head fancyCard__head--alt">
                                    <p><strong>Placebo </strong>n=87
                                    </p>
                                </th>
                            </tr>
                            <tr>
                                <td class="fancyCard__content  fancyCard__content--larger fancyCard__content--alt">
                                    <p>Gastrointestinal disorder,n(%)</p>
                                </td>
                                <td class="fancyCard__content ">
                                    <p></p>
                                </td>
                                <td class="fancyCard__content ">
                                    <p></p>
                                </td>
                            </tr>
                            <tr>
                                <td class="fancyCard__content fancyCard__content--larger">
                                    <p>Abdominal pain</p>
                                </td>
                                <td class="fancyCard__content ">
                                    <p>16 (8.9%)</p>
                                </td>
                                <td class="fancyCard__content ">
                                    <p>6 (6.9%)</p>
                                </td>
                            </tr>
                            <tr>
                                <td class="fancyCard__content fancyCard__content--larger">
                                    <p>Diarrhea</p>
                                </td>
                                <td class="fancyCard__content ">
                                    <p>13 (7.2%)</p>
                                </td>
                                <td class="fancyCard__content ">
                                    <p>3 (3.4%)</p>
                                </td>
                            </tr>

                        </table>

                    </div>
                </div>

                <h3 class="fancyCard__bottomTitle">In all patients within the blinded portion of the phase 3 trial
                    (safety population)<sup>1,3</sup></h3>
                <ul class="fancyCard__list">
                    <li>No serious adverse reactions occurred within 8 weeks following administration of blinded or
                        open-label REBYOTA or placebo treatment in the trial </li>
                    <li>Discontinuation due to adverse reactions = 1.1% (2/180) of patients</li>
                </ul>

                <div class="fancyCard__textBottom">
                    <p><sup>c</sup>Treatment success was defined as no CDI-related diarrhea at 8
                        weeks.<sup>1,3</sup>
                    </p>
                </div>
            </div>
        </section>

        <section class="fancyCard">
            <div class="container">
                <div class="fancyCard__top fancyCard__top--alt">
                    <h2 class="sectionTitle__title"><span
                            class="logo logo--large"><strong>RE</strong>BYOTA</span><strong>
                            DURABILITY MAINTAINED</strong> THROUGH 24 MONTHS
                    </h2>
                    <p><strong>In the PUNCHâ¢ open-label trialâ¦<sup>4</sup></strong></p>
                </div>
                <div class="fancyCard__wrap">
                    <div class="fancyCard__wrapInner">
                        <div class="fancyCard__flex">
                            <figure class="fancyCard__imageLarge">
                                <img src="<?php echo get_template_directory_uri() ?> /uploads/flower3.png"
                                    alt="Flower Image" />
                            </figure>
                            <div class="fancyCard__description fancyCard__description--flex">
                                <p><strong>Treatment success was met in 78.9% (112/142) of patients at 8
                                        weeks.<br />Historic control was 30.7% (23/75).</strong>
                                </p>
                                <p>Post hoc analysis indicated that <strong>90.7% (88/97)</strong> of patients who
                                    saw success
                                    <strong>had a sustained response through 24 months.<br />Historic control was
                                        not calculated.</strong>
                                </p>
                                <hr class="tab__underline">
                                <p class="lineHeight">
                                    <strong>Study Design</strong>: Multicenter, open-label phase 2 study in patients
                                    with multiple
                                    recurrences of CDI who had â¤2 REBYOTA doses<sup>f</sup> administered 7Â±2 days
                                    apart.g
                                    CDI-diarrhea absence at 8 weeks after the last treatment defined treatment
                                    success (primary endpoint), which was compared with rCDI-free rates at 8 weeks
                                    for a matched historical group that had received standard-of-care antibiotics.
                                    Safety was monitored for up to 24 months. Efficacy at month 24 was reported as a
                                    post hoc analysis.
                                </p>
                            </div>

                        </div>
                    </div>
                </div>
                <ul class="fancyCard__list">
                    <li>Of the 149 participants treated with REBYOTA, 123 (83%) experienced a total of 805
                        treatment-emergent AEs.<sup>4</sup> The majority were related to preexisting conditions or C.
                        <em>difficile</em>
                        infection
                    </li>
                </ul>
                <div class="fancyCard__textBottom">
                    <p><sup>f</sup>96% (143/149) of patients received 2 REBYOTA doses and 4% (6/149) received 1
                        dose.<sup>4</sup>
                        <br><sup>g</sup>Dosing in the REBYOTA clinical program, including PUNCH<sup>TM</sup> CD3, was
                        based on data from a
                        double-blind, placebo-controlled phase 2b trial in patients with â¥2 rCDI, which showed that a
                        single REBYOTA dose produced maximal benefit after an rCDI episode.<sup>1,3</sup> The phase 2b
                        study
                        randomized patients to: 2 REBYOTA doses (group A; n=41), 2 placebo doses (group B; n=44), or 1
                        REBYOTA dose followed by 1 placebo dose (group C; n=42). rCDI prevention for 8 weeks post
                        treatment defined efficacy, with rCDI within 8 weeks rendering patients eligible for up to 2
                        open-label REBYOTA doses. For groups A, B, and C, efficacy was respectively 61%, 45%, and 67%;
                        the primary endpointâefficacy for groups A vs Bâwas not met. One REBYOTA dose (group C) was
                        superior to placebo (group B). There was no significant difference in AEs among the 3 groups
                        through a mean 8.3-month follow-up, with safety monitored through 24 months.
                    </p>
                </div>
            </div>
        </section>
    </div>

    <section class="fancyCard">
        <div class="container">
            <div class="fancyCard__textDescription">
                <h2 class="sectionTitle__title">HOW <span class="logo logo--large"><strong>RE</strong>BYOTA</span> WORKS
                </h2>
                <p>While the exact mechanism of action is not fully understoodâ¦<br>
                    REBYOTA is thought to involve repopulation and restoration of the composition and diversity
                    of the gut microbiome to suppress C. difficile outgrowth and CDI recurrence<sup>1</sup></p>
            </div>
            <ul class="fancyCard__list">
                <li>In clinical trials, treatment success was associated with increased relative abundance of
                    Clostridia- and Bacteroidia-class bacteria and decreased relative abundance of Gammaproteobacteria-
                    and Bacilli-class bacteria<sup>1</sup>
                </li>
            </ul>

            <div class="fancyCard__center">
                <div class="fancyCard__wrap fancyCard__wrap--alt">
                    <div class="fancyCard__wrapInner fancyCard__wrapInner--center">
                        <h3 class="fancyCard__chartHead">
                            Shift in microbiome diversity following administration
                            (demonstrated in PUNCH<sup>TM</sup> open-label trial)<sup>4,a</sup>
                        </h3>
                        <figure class="fancyCard__chart">
                            <img src="<?php echo get_template_directory_uri() ?> /uploads/chart.png" alt="Chart" />
                        </figure>
                    </div>
                </div>
            </div>
            <div class="fancyCard__textDescription">
                <p><strong>REBYOTA also showed a shift to secondary bile acid dominance<sup>1</sup></strong></p>
                <p>REBYOTA administration was also associated with a shift in gut bile acid compositions of secondary
                    bile acid predominance, which has been associated with suppressions of C. difficile outgrowth and
                    CDI recurrence in animal studies</p>
            </div>
            <div class="fancyCard__textBottom">
                <p><sup>a</sup>For illustrative purposes only.
                </p>
            </div>
        </div>
    </section>

    <div class="backgroundWrapper"
        style="background-image: url('<?php echo get_template_directory_uri(); ?>/uploads/backgroundWrapper.jpg')">

        <section class="fancyCard">
            <div class="container">
                <h2 class="sectionTitle__title"><span
                        class="logo logo--large"><strong>RE</strong>BYOTA<sup>Â®</sup></span><strong> ADMINISTRATION
                    </strong>
                </h2>
                <div class="sectionTitle__title">
                    <p><span class="logo logo--large"><strong>RE</strong>BYOTAâ</span>ONE DOSE.<br>ONE COMPLETE
                        MICROBIOME
                        TREATMENT</p>
                </div>
                <div class="fancyCard__textDescription">
                    <p><strong>Delivered within minutes by a healthcare professional.</strong></p>
                </div>

                <div class="fancyCard__wrap fancyCard__wrap--alt fancyCard__wrap--fullWidth">
                    <div class="fancyCard__wrapInner fancyCard__wrapInner--padding">
                        <div class="fancyCard__flex">
                            <div class="fancyCard__flexContent">
                                <h3 class="fancyCard__header">
                                    BEFORE
                                </h3>
                                <p>Request that patient empty bladder and bowel, if possible.</p>
                                <p>Place patient in the preferred position: either a left-side or
                                    knee-chest position.<sup>1</sup></p>
                            </div>
                            <div class="fancyCard__flexContent">
                                <h3 class="fancyCard__header">
                                    DURING
                                </h3>
                                <p>Lubricate and gently insert the provided administration tube into the rectum about
                                    5 inches pointed slightly toward the navel.</p>
                                <p>Hold the administration tube, with the other hand open the pinch clamp, and
                                    graduallys
                                    raise to allow the product to flow via gravity.</p>
                            </div>
                            <div class="fancyCard__flexContent">
                                <h3 class="fancyCard__header">
                                    AFTER
                                </h3>
                                <p>After instilling product, withdraw tube, and keep patient in position for up to
                                    15 minutes to minimize possible cramping.</p>
                                <p>Some product will remain in the tube; this is normal and does not affect
                                    treatment.<sup>1</sup>
                                </p>
                            </div>
                        </div>
                        <hr class="tab__underline">
                        <h3 class="fancyCard__header">
                            important considerations<sup>1</sup>
                        </h3>
                        <ul class="fancyCard__list">
                            <li><strong>DO NOT</strong> administer REBYOTA during antibiotic treatment for CDI </li>
                            <li>It is recommended to administer REBYOTA from 24 to approximately 72 hours after the last
                                dose of antibiotics</li>
                            <li>The REBYOTA carton can be stored either in an ultracold freezer, -76Â°F to -130Â°F until
                                its expiration or stored in the refrigerator, 36Â°F to 46Â°F for up to 4 days</li>
                            <li><strong>Prior to use,</strong> thaw REBYOTA completely by placing the carton in either a
                                refrigerator, 36Â°F to 46Â°F for approximately 24 hours or placing the carton at room
                                temperature until thawed</li>

                        </ul>
                        <div class="fancyCard__button">
                            <a href="#" class="button">FULL Instructions For Use
                            </a>
                        </div>

                    </div>
                </div>


        </section>

        <section class="cardBlock">
            <div class="container">
                <div class="cardBlock__wrapper">

                    <div class="cardBlock__card">
                        <figure class="cardBlock__img">
                            <img src="<?php echo get_template_directory_uri() ?>/uploads/card.jpg" alt="Card Image" />
                        </figure>
                        <h2 class="cardblock__title">
                            REBYOTA Clinical Data
                        </h2>
                        <p>Explore clinical data evaluating the efficacy
                            and safety of REBYOTA to treat
                            recurrent C. difficile infection (rCDI). </p>
                        <a href="#" class="button">Clinical Data</a>
                    </div>

                    <div class="cardBlock__card">
                        <figure class="cardBlock__img">
                            <img src="<?php echo get_template_directory_uri() ?>/uploads/card.jpg" alt="Card Image" />
                        </figure>
                        <h2 class="cardblock__title">
                            REBYOTA ADMINISTRATION
                        </h2>
                        <p>Learn how to administer REBYOTAâone dose, one complete microbiome treatment. </p>
                        <a href="#" class="button">Administration</a>
                    </div>

                </div>
            </div>
        </section>

    </div>
    <section class="accordion">
            <div class="accordion__top">
                <div class="container">
                    <div class="accordion__topWrapper">
                        <h2 class="accordion__topTitle">Important Safety information</h2>
                        <div class="accordion__accoridoinButton" type="button">
                            <svg class="icon accordion__icon icon-minus">
                                <use xlink:href="#icon-minus"></use>
                            </svg>
                            <button class="accordion__plus" type="button">
                                <svg class="icon accordion__icon icon-plus">
                                    <use xlink:href="#icon-plus"></use>
                                </svg>
                            </button>
                        </div>
                    </div>
                </div>
            </div>
            <div class="accordion__body">
                <div class="container">
                    <div class="accordion__wrap">
                        <h3 class="accordion__title">Indication For Use</h3>
                        <p>REBYOTA (bacrodiome-mcrb) is indicated to reduce the recurrence of Clostridioides difficile
                            infection (CDI) in adults following antibiotic treatment for recurrent CDI.</p>
                        <h3 class="accordion__title">Important Safety Information</h3>
                        <p><strong class="accordion__subTitle">Contraindications</strong></p>
                        <p>REBYOTA has no identified contraindications.</p>
                        <p><strong class="accordion__subTitle">Warnings and Precautions</strong></p>
                        <p>No serious hypersensitivity reactions have been reported in patients treated with REBYOTA. Do
                            not use in patients with a previous hypersensitivity to REBYOTA or any of the product
                            components.</p>
                        <p><strong class="accordion__subTitle">Adverse Reactions</strong></p>
                        <p>The most common adverse reactions following blinded treatment with REBYOTA (reported by â¥5%
                            of all subjects and greater than placebo) were diarrhea and abdominal pain.</p>
                        <p><strong class="accordion__subTitle"> Interactions</strong></p>
                        <p>Since REBYOTA is not absorbed into the body, no metabolic drug-drug interactions are
                            expected.</p>
                        <p><strong class="accordion__subTitle">Use In Specific Populations</strong></p>
                        <p class="accordion__subTitle">Geriatric Use</p>
                        <p>Of the 749 patients treated with REBYOTA, 47.9% were â¥65 years of age, and 25.8% were â¥75
                            years of age. No overall differences in safety and efficacy were observed between these
                            subjects and younger subjects. No dose adjustment is necessary for patients â¥65 years of
                            age.</p>
                        <p>You are encouraged to report negative side effects of prescription drugs to FDA. Visit
                            www.FDA.gov/medwatch, or call 1-800-FDA-1088. </p>
                        <a href="#" class="accordion__link">
                            <p>Please click here for full Prescribing Information. </p>
                        </a>
                    </div>
                </div>
                <div class="accordion__bottom">
                    <div class="container">
                        <h3 class="accordion__bottomTitle">References</h3>
                        <ol class="accordion__list">
                            <li>Rebyota. Prescribing Information. Parsippany, NJ: Ferring Pharmaceuticals Inc; 2022.
                            </li>
                            <li>Sicard J-F, Le Bihan G, Vogeleer P, Jacques M, Harel J. Interactions of intestinal
                                bacteria
                                with components of intestinal mucus. Front Call Infect Microbiol. 2017;7:387.
                                doi:10.3389/fcimb.2017.00387
                            </li>
                        </ol>
                    </div>
                </div>
            </div>
        </section>




</main>
<?php get_footer(); ?>